Table 5. Correlation of the expression of DCK, hENT-1 and RRM-1 with the drug response pattern using HDRA and the clinicopathological data of CCA patients.

Variables	N (33)	DCK			hENT-1			RRM1
		Low	High	p	Low	High	p	Low	High	p
1000 μg/ml gemcitabine
Non-response	27	15	12	1.000	24	3	0.268	16	11	0.241
Response	7	4	3		5	2		2	5
1500 μg/ml gemcitabine
Resistance	28	16	12	1.000	27	1	0.002*	14	14	0.660
Sensitive	6	3	3		2	4		4	2
Sex
Male	19	13	6	0.165	14	5	0.053	12	7	0.300
Female	15	6	9		15	0		6	9
Age (year)
Less than 63	16	7	9	0.300	14	2	1.000	9	7	0.744
63 or greater	18	12	6		15	3		9	9
Tumor site
Intrahepatic	22	14	8	0.288	18	4	0.635	9	13	0.080
Extrahepatic	12	5	7		11	1		9	3
Histology
Papillary	13	8	5	0.728	13	0	0.132	8	5	0.497
Non-papillary	21	11	10		16	5		10	11
Marginal status
Free margin	18	11	7	0.411	15	3	0.677	12	6	0.199
Not free margin	12	5	7		11	1		4	8
Not applicable	4	3	1		3	1		2	2
Primary tumor (T)
Is, I, II	10	5	5	0.878	8	2	0.251	6	4	0.290
III, IV	22	13	9		20	2		10	12
Not applicable	2	1	1		1	1		2	0
Reginal lymph node (N) metastasis
No	17	11	6	0.442	16	1	0.344	10	7	0.769
Yes	8	3	5		6	2		4	4
Not applicable	9	5	4		7	2		4	5
Distance metastasis (M)
No	17	8	9	0.389	15	2	0.281	9	8	0.704
Yes	6	3	3		6	0		4	2
Not applicable	11	8	3		8	3		5	6
TNM stage
I,II	8	5	3	0.581	6	2	0.025*	5	3	0.490
III,IV	25	13	12		23	2		12	13
Stage unknown	1	1	0		0	1		1	0

*P<0.005, statistically significant